Skip to content

Author: Revier Therapeutics GmbH

Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease

August 25, 2026

All content ©2025 Tork Media
All Rights Reserved. For more information on this site, please read our Privacy Policy, Terms of Service, Cookie Policy, and Ad Choices.